Education
About Us
Working with TipRanks
Follow Us
BriaCell Therapeutics Corp (TSE:BCT)
TSX:BCT
Cyclophosphamide, Sv-Br-1-Gm, Retifanlimab, Interferon Infiltration Of The Inoculation Site, Treatment Of Physician's Choice
Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer
Phase III
Recruiting
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Sep 25, 2023
―
Sv-Br-1-Gm, Low Dose Cyclophosphamide, Interferon Inoculation, Retifanlimab
Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic
Phase I/II
Enrolling By Invitation
Combination Study of SV-BR-1-GM With Retifanlimab
Oct 23, 2017
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does BriaCell Therapeutics Corp (BCT) have in its pipeline
BCT is currently developing the following drugs: Cyclophosphamide, Sv-Br-1-Gm, Retifanlimab, Interferon Infiltration Of The Inoculation Site, Treatment Of Physician's Choice, Sv-Br-1-Gm, Low Dose Cyclophosphamide, Interferon Inoculation, Retifanlimab. These drug candidates are in various stages of clinical development as the company works toward FDA approval.